Drug Trial Radar · NCT02702180
Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Mar 21, 2016
Primary completion
Apr 19, 2019
Study completion Sep 27, 2019
Sponsor
- Lead sponsor
- Savara Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 8, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates inhaled molgramostim (recombinant human granulocyte macrophage-colony stimulating factor \[rhGM-CSF\]) in the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) patients. A third of the patients will receive inhaled molgramostim once daily for 24 weeks, a third will receive inhaled molgramostim intermittently (7 days on, 7 days off) for 24 weeks and a third will receive inhaled matching placebo for 24 weeks.
Conditions
- Autoimmune Pulmonary Alveolar Proteinosis
Interventions
MolgramostimDrug
300 mcg molgramostim (rhGM-CSF) nebulizer solution for inhalation
PlaceboDrug
Placebo nebulizer solution for inhalation
PARI eFlow nebulizer systemDevice
PARI eFlow nebulizer system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline of Alveolar-arterial Oxygen Concentration (A-a(DO2)) After 24 Weeks of TreatmentTime frame: From baseline to 24 weeks
Locations
30 sites in 18 countries. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
University of Florida
Gainesville, Florida
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Aarhus University Hospital
Aarhus, Denmark
CHU Rennes Hospital Pontchaillou
Rennes, France
Westdeutsches Lungenzentrum am Universitätsklinikum Essen
Essen, Germany
Asklepios Fachkliniken München - Gauting
Gauting, Germany
Thoraxklinik am Universitätsklinikum Heidelberg
Heidelberg, Germany
Universitätsklinikum Schleswig-Holstein Zentralklinikum, Lübeck Medizinische Klinik III, Pneumologie
Lübeck, Germany
Attikon University Hospital
Athens, Greece
Rabin Medical Center
Petah Tikva, Israel
IRCCS Policlinico San Matteo
Pavia, Italy
Niigata University Medical and Dental Hospital
Niigata, Japan
National Hospital Organization Kinki-Chuo
Osaka, Japan
Tohoku University Hospital
Sendai, Japan
Aichi Medical University Hospital
Toyohashi, Japan
Kanagawa Cardiovascular and Respiratory Center
Yokohama, Japan
St. Antonius Hospital
Nieuwegein, Netherlands
Hospital de dia de Pneumologia
Lisbon, Portugal
Hospital Sao Joao
Porto, Portugal
City Hospital St. Petersburg
Saint Petersburg, Russia
II. Pulmonary Department National Institut for TB, Lung Diseases and Chest Surgery
Vyšné Hágy, Slovakia
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center, Division of Pulmonary and Critical Care Medicine
Seoul, South Korea
Samsung Medical Center, Division of Pulmonary and Critical Care Medicine
Seoul, South Korea
Hospital University de Bellvitge (HUB)
Barcelona, Spain
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
Yedikule Pulmonary Diseases and Pulmonary Surgery Training and Research Hospital
Istanbul, Turkey (Türkiye)
Royal Brompton Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.